Uganda
clears three experimental Ebola treatments, watches for
spread
Send a link to a friend
[June 18, 2019]
By Elias Biryabarema
KAMPALA (Reuters) - Health workers have got
the all-clear to use three experimental Ebola treatments in Uganda, a
week after the deadly disease spread over the border from Democratic
Republic of Congo, authorities said on Tuesday.
|
Two people who had traveled from Congo died in Uganda last week, the
World Health Organization said. A three-year-old boy who was sent
back to Congo after testing positive for the disease died at the
weekend, Congo's health ministry said.
At least another 1,411 people have died in Congo since August in the
second worst outbreak of the disease on record.
"Happy to inform you all that we got clearance from both Uganda
National Council for Science and Technology and National Drug
Authority to bring in the Therapeutic treatment for #Ebola patients
in the country," Uganda's Health Minister, Jane Ruth Aceng, said on
Twitter.
The treatments approved for shipment to Uganda were Mapp
Biopharmaceutical's ZMapp, Regeneron Pharmaceuticals Inc's Regeneron
and Remdesivir, made by Gilead Sciences, said WHO spokesman Tarik
Jasarevic.
“The protocols for the fourth being submitted. Logistics underway
with MSF support for importation of a few courses about 10 each,” he
added in an email.
The U.N. health agency has said there have so far been no known
cases of Ebola spreading between people in Uganda - all recorded
patients had traveled in from Congo.
[to top of second column] |
Four experimental therapeutic treatments are already being used in
Congo, it added.
On Friday, a WHO panel decided not to declare an international
emergency over Congo's Ebola outbreak despite its spread to Uganda,
saying such a declaration could cause too much economic harm.
"Obviously, the crisis is far from over," Mark Green, the head of
the U.S. Agency for International Development (USAID), told a news
conference in Nairobi.
Health workers and people who came in contact with infected people
began receiving a Merck experimental vaccine in Uganda on Saturday.
(Additional reporting by Tom Miles and Stephanie Nebehay in Geneva,
Omar Mohammed in Nairobi and Kate Kelland in London; Writing by
George Obulutsa)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|